company background image
QURE logo

uniQure NasdaqGS:QURE Voorraadrapport

Laatste prijs

US$5.56

Marktkapitalisatie

US$285.4m

7D

-16.8%

1Y

-9.0%

Bijgewerkt

04 Nov, 2024

Gegevens

Financiële gegevens bedrijf +

uniQure N.V.

NasdaqGS:QURE Voorraadrapport

Marktkapitalisatie: US$285.4m

QURE Overzicht aandelen

uniQure N.V. ontwikkelt behandelingen voor patiënten die lijden aan zeldzame en andere verwoestende ziekten.

uniQure N.V. Concurrenten

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor uniQure
Historische aandelenkoersen
Huidige aandelenkoersUS$5.56
52 Week HoogtepuntUS$11.35
52 Week LaagUS$3.73
Bèta0.94
11 maand verandering-1.59%
3 maanden verandering-26.46%
1 Jaar Verandering-9.00%
33 jaar verandering-84.35%
5 jaar verandering-89.65%
Verandering sinds IPO-61.94%

Recent nieuws en updates

uniQure's Yellow Flags: Early-Stage Gene Therapies Amid Restructuring

Oct 21

uniQure: Pullback After Strong Interim Treatment Data Creates Buying Opportunity

Aug 06

uniQure N.V. (NASDAQ:QURE) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Aug 03
uniQure N.V. (NASDAQ:QURE) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Recent updates

uniQure's Yellow Flags: Early-Stage Gene Therapies Amid Restructuring

Oct 21

uniQure: Pullback After Strong Interim Treatment Data Creates Buying Opportunity

Aug 06

uniQure N.V. (NASDAQ:QURE) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Aug 03
uniQure N.V. (NASDAQ:QURE) Analysts Are Cutting Their Estimates: Here's What You Need To Know

uniQure: Positive HD AMT-130 Treatment Data Leads To Several Other Catalysts

Jul 09

Earnings Update: uniQure N.V. (NASDAQ:QURE) Just Reported And Analysts Are Trimming Their Forecasts

Mar 03
Earnings Update: uniQure N.V. (NASDAQ:QURE) Just Reported And Analysts Are Trimming Their Forecasts

uniQure: The Valuation Got More Attractive

Feb 01

Little Excitement Around uniQure N.V.'s (NASDAQ:QURE) Revenues As Shares Take 29% Pounding

Jan 17
Little Excitement Around uniQure N.V.'s (NASDAQ:QURE) Revenues As Shares Take 29% Pounding

A Look At The Fair Value Of uniQure N.V. (NASDAQ:QURE)

Dec 15
A Look At The Fair Value Of uniQure N.V. (NASDAQ:QURE)

Revenue Downgrade: Here's What Analysts Forecast For uniQure N.V. (NASDAQ:QURE)

Aug 27
Revenue Downgrade: Here's What Analysts Forecast For uniQure N.V. (NASDAQ:QURE)

Analysts Are More Bearish On uniQure N.V. (NASDAQ:QURE) Than They Used To Be

Aug 06
Analysts Are More Bearish On uniQure N.V. (NASDAQ:QURE) Than They Used To Be

Here's Why uniQure (NASDAQ:QURE) Can Manage Its Debt Despite Losing Money

Aug 02
Here's Why uniQure (NASDAQ:QURE) Can Manage Its Debt Despite Losing Money

uniQure N.V. (NASDAQ:QURE) Looks Inexpensive After Falling 43% But Perhaps Not Attractive Enough

Jul 02
uniQure N.V. (NASDAQ:QURE) Looks Inexpensive After Falling 43% But Perhaps Not Attractive Enough

Analyst Forecasts For uniQure N.V. (NASDAQ:QURE) Are Surging Higher

Jun 28
Analyst Forecasts For uniQure N.V. (NASDAQ:QURE) Are Surging Higher

uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year

May 14
uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year

Is uniQure (NASDAQ:QURE) Using Debt Sensibly?

Apr 11
Is uniQure (NASDAQ:QURE) Using Debt Sensibly?

News Flash: 15 Analysts Think uniQure N.V. (NASDAQ:QURE) Earnings Are Under Threat

Mar 01
News Flash: 15 Analysts Think uniQure N.V. (NASDAQ:QURE) Earnings Are Under Threat

Does uniQure (NASDAQ:QURE) Have A Healthy Balance Sheet?

Dec 09
Does uniQure (NASDAQ:QURE) Have A Healthy Balance Sheet?

uniQure: Clinical Risk, A Critical Upcoming Catalyst And A Cash Cushion

Sep 21

uniQure N.V.: 2 Possible Regulatory Approvals Makes This A Must Watch

Aug 30

uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year

Aug 14
uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year

uniQure plunges 27% on Q2 revenue miss, postpones higher dose trial of Huntington’s disease therapy

Aug 08

These 4 Measures Indicate That uniQure (NASDAQ:QURE) Is Using Debt Safely

Jun 08
These 4 Measures Indicate That uniQure (NASDAQ:QURE) Is Using Debt Safely

uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year

May 04
uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year

uniQure N.V.: Worth A Look Based On Hemophilia B Marketing Applications

Apr 08

We Think That There Are Issues Underlying uniQure's (NASDAQ:QURE) Earnings

Mar 04
We Think That There Are Issues Underlying uniQure's (NASDAQ:QURE) Earnings

The Consensus EPS Estimates For uniQure N.V. (NASDAQ:QURE) Just Fell Dramatically

Feb 27
The Consensus EPS Estimates For uniQure N.V. (NASDAQ:QURE) Just Fell Dramatically

Is uniQure (NASDAQ:QURE) A Risky Investment?

Feb 23
Is uniQure (NASDAQ:QURE) A Risky Investment?

uniQure: Betting On Hemophilia-B Cure

Jan 18

Rendement voor aandeelhouders

QUREUS BiotechsUS Markt
7D-16.8%-1.4%-1.9%
1Y-9.0%20.2%30.4%

Rendement versus industrie: QURE presteerde slechter dan de US Biotechs -sector, die het afgelopen jaar een rendement van 20.2 % opleverde.

Rendement versus markt: QURE presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 30.4 % opleverde.

Prijsvolatiliteit

Is QURE's price volatile compared to industry and market?
QURE volatility
QURE Average Weekly Movement11.4%
Biotechs Industry Average Movement9.6%
Market Average Movement6.0%
10% most volatile stocks in US Market15.0%
10% least volatile stocks in US Market2.9%

Stabiele aandelenkoers: De aandelenkoers van QURE is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 11% ) van QURE is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen US.

Over het bedrijf

OpgerichtWerknemersCEOWebsite
1998480Matt Kapustawww.uniqure.com

uniQure N.V. ontwikkelt behandelingen voor patiënten die lijden aan zeldzame en andere verwoestende ziekten. Het biedt HEMGENIX aan, dat de Fase III HOPE-B studie voor de behandeling van hemofilie B heeft voltooid. Het bedrijf ontwikkelt ook AMT-130, een gentherapie die zich in Fase I/II klinische studie bevindt voor de behandeling van de ziekte van Huntington.

uniQure N.V. Samenvatting

Hoe verhouden de winst en inkomsten van uniQure zich tot de beurswaarde?
QURE fundamentele statistieken
MarktkapitalisatieUS$285.37m
Inkomsten(TTM)-US$284.69m
Inkomsten(TTM)US$27.71m

9.8x

P/S-verhouding

-1.0x

Koers/Winstverhouding

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
QURE resultatenrekening (TTM)
InkomstenUS$27.71m
Kosten van inkomstenUS$195.83m
Brutowinst-US$168.12m
Overige uitgavenUS$116.57m
Inkomsten-US$284.69m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)-5.85
Brutomarge-606.80%
Nettowinstmarge-1,027.52%
Schuld/Eigen Vermogen Verhouding533.9%

Hoe presteerde QURE op de lange termijn?

Bekijk historische prestaties en vergelijking